Medical foods in Alzheimer’s disease
Alzheimer’s disease (AD) is the most prevalent cause of dementia worldwide. Treatments achieving a marked improvement in symptoms or preventing or delaying the progression of the disease are not available. Various diet-related risk factors for AD have been identified. Evidence for a protective effec...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tsinghua University Press
2019-03-01
|
| Series: | Food Science and Human Wellness |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213453019300059 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557582018936832 |
|---|---|
| author | Klaus W. Lange Jianjun Guo Shigehiko Kanaya Katharina M. Lange Yukiko Nakamura Shiming Li |
| author_facet | Klaus W. Lange Jianjun Guo Shigehiko Kanaya Katharina M. Lange Yukiko Nakamura Shiming Li |
| author_sort | Klaus W. Lange |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the most prevalent cause of dementia worldwide. Treatments achieving a marked improvement in symptoms or preventing or delaying the progression of the disease are not available. Various diet-related risk factors for AD have been identified. Evidence for a protective effect of the Mediterranean diet on AD risk is inconclusive. Medical foods are designed to meet specific dietary needs for certain diseases. Improvements in symptomatology and regional brain atrophy in AD have been claimed for several medical foods, for example, those providing ketone bodies as alternative energy supply to neurons, those containing precursors believed to improve synaptic function, and those addressing oxidative stress related to memory loss. Many methodological shortcomings render the interpretation of the available findings of medical food trials in AD difficult. Optimal results of medical foods in AD may be expected when administered in presymptomatic or early stages of the disease. This requires the reliable identification of minimal neuropathological changes related to AD. The outcome measures currently used may not be able to detect subtle changes in cognition and function in early AD. Large-scale clinical studies using valid, sensitive, and reliable assessment tools are needed to establish the efficacy of medical foods in AD. Keywords: Alzheimer’s disease, Ketogenic diet, Medical foods, Mediterranean diet, Nutrition |
| format | Article |
| id | doaj-art-7238b38efe75474992e4de97cab44033 |
| institution | Kabale University |
| issn | 2213-4530 |
| language | English |
| publishDate | 2019-03-01 |
| publisher | Tsinghua University Press |
| record_format | Article |
| series | Food Science and Human Wellness |
| spelling | doaj-art-7238b38efe75474992e4de97cab440332025-02-03T04:08:04ZengTsinghua University PressFood Science and Human Wellness2213-45302019-03-018117Medical foods in Alzheimer’s diseaseKlaus W. Lange0Jianjun Guo1Shigehiko Kanaya2Katharina M. Lange3Yukiko Nakamura4Shiming Li5Department of Experimental Psychology, University of Regensburg, 93040 Regensburg, Germany; Corresponding author at: Institute of Psychology, University of Regensburg, 93040 Regensburg, Germany.China Institute of Sport Science, Beijing, ChinaGraduate School of Information Science, Nara Institute of Science and Technology, Ikoma, JapanDepartment of Psychology, University of Winchester, Winchester, United KingdomDepartment of Experimental Psychology, University of Regensburg, 93040 Regensburg, GermanyDepartment of Food Science, Rutgers University, New Brunswick, NJ, USAAlzheimer’s disease (AD) is the most prevalent cause of dementia worldwide. Treatments achieving a marked improvement in symptoms or preventing or delaying the progression of the disease are not available. Various diet-related risk factors for AD have been identified. Evidence for a protective effect of the Mediterranean diet on AD risk is inconclusive. Medical foods are designed to meet specific dietary needs for certain diseases. Improvements in symptomatology and regional brain atrophy in AD have been claimed for several medical foods, for example, those providing ketone bodies as alternative energy supply to neurons, those containing precursors believed to improve synaptic function, and those addressing oxidative stress related to memory loss. Many methodological shortcomings render the interpretation of the available findings of medical food trials in AD difficult. Optimal results of medical foods in AD may be expected when administered in presymptomatic or early stages of the disease. This requires the reliable identification of minimal neuropathological changes related to AD. The outcome measures currently used may not be able to detect subtle changes in cognition and function in early AD. Large-scale clinical studies using valid, sensitive, and reliable assessment tools are needed to establish the efficacy of medical foods in AD. Keywords: Alzheimer’s disease, Ketogenic diet, Medical foods, Mediterranean diet, Nutritionhttp://www.sciencedirect.com/science/article/pii/S2213453019300059 |
| spellingShingle | Klaus W. Lange Jianjun Guo Shigehiko Kanaya Katharina M. Lange Yukiko Nakamura Shiming Li Medical foods in Alzheimer’s disease Food Science and Human Wellness |
| title | Medical foods in Alzheimer’s disease |
| title_full | Medical foods in Alzheimer’s disease |
| title_fullStr | Medical foods in Alzheimer’s disease |
| title_full_unstemmed | Medical foods in Alzheimer’s disease |
| title_short | Medical foods in Alzheimer’s disease |
| title_sort | medical foods in alzheimer s disease |
| url | http://www.sciencedirect.com/science/article/pii/S2213453019300059 |
| work_keys_str_mv | AT klauswlange medicalfoodsinalzheimersdisease AT jianjunguo medicalfoodsinalzheimersdisease AT shigehikokanaya medicalfoodsinalzheimersdisease AT katharinamlange medicalfoodsinalzheimersdisease AT yukikonakamura medicalfoodsinalzheimersdisease AT shimingli medicalfoodsinalzheimersdisease |